ADCE-B05 / Adcendo - LARVOL DELTA

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Adcendo ApS

First-in-human • New P1 trial • Oncology • Solid Tumor

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline (PRNewswire) - "Adcendo...announced the successful closing of an oversubscribed $135 million Series B financing round. Proceeds from the fundraise will be used to advance, broaden, and accelerate the development of the Company's first-in-class ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programs. The financing round was led by TCGX, with participation from new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, as well as all existing investors, including RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital."

Financing • Oncology